Reproductive · FDA Approved
Ganirelix
FDA-approved
01 · Overview
A synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph cells.
GnRH antagonists such as ganirelix inhibit gonadotropin release within several hours, preventing premature LH surges during assisted reproductive technology (ART) cycles without the flare phase of GnRH agonists (PMID 27126581).
02 · Research summary & key findings
FDA-approved for inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. In a North American phase 3 trial, ganirelix gave similar pregnancy rates to a long leuprolide protocol with a shorter treatment duration, though fewer oocytes were retrieved (PMID 11163814). In a European trial, ganirelix required a median 5 days of analogue treatment versus 26 days for buserelin, with OHSS in 2.4% versus 5.9% (PMID 10875855). A Cochrane review found antagonist protocols reduce OHSS without lowering live birth rates compared with long agonist protocols (PMID 27126581).
03 · Regulatory status
Ganirelix has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Ganirelix is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Ganirelix is prescribed for the conditions on its label, and it is not part of our intake. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group Hum Reprod, 2000. PMID 10875855
- [2]Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation Fertil Steril, 2001. PMID 11163814
- [3]Gonadotrophin-releasing hormone antagonists for assisted reproductive technology Cochrane Database Syst Rev, 2016. PMID 27126581
Primary literature
- PubMed: "Ganirelix"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Ganirelix"
Registered interventional and observational studies, including status and phase.
- PubChem: "Ganirelix"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Reproductive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.